Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 2273-2274, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia-Barceló, M.
Right arrow Articles by Waye, M. M. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia-Barceló, M.
Right arrow Articles by Waye, M. M. Y.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:2273-2274.)
© 1999 American Association for Clinical Chemistry, Inc.

Technical Briefs

Frequencies of Defective CYP2C19 Alleles in a Hong Kong Chinese Population: Detection of the Rare Allele CYP2C19*4

Mercè Garcia-Barceló1,a, Lok-Yee Chow1, Helen Fung Kum Chiu1, Yun Kowk Wing1, Dominic Tak Shing Lee1, Kwok Lim Lam1 and Mary Miu Yee Waye2

1 Psychiatry and
2 Biochemistry, The Chinese University of Hong Kong, Hong Kong;
a author for correspondence: fax 852-2646-2284, e-mail b025744@mailserv.cuhk.edu.hk

A genetic polymorphism in the metabolism of the anticonvulsant drug mephenytoin in humans is a prime example of interracial and individual variability in drug metabolism. This polymorphism affects the metabolism of several other clinically used drugs, some of which are of interest in psychopharmacotherapy (1). The polymorphic enzyme that 4'-hydroxylates S-mephenytoin is known as CYP2C19 (2). In subjects deficient for CYP2C19, drugs metabolized by this enzyme may be associated with toxic concentrations or therapeutic failure when administered in dosages within the normal dosage range. Depending on the activity of CYP2C19, individuals can be characterized phenotypically as extensive metabolizers or poor metabolizers (PMs) of S-mephenytoin. CYP2C19 is encoded by the CYP2C19 gene, and its defective alleles account for the PM phenotype, which is inherited as an autosomal recessive trait (3). There is a marked interethnic difference in the distribution of this polymorphism, with the PM phenotype found in 2–5% of Caucasians but in 13–23% of Orientals (4)(5). The main defective allele, CYP2C192, accounts for ~75–85% of alleles responsible for the PM phenotype in both Orientals and Caucasians (4). . . . [Full Text of this Article]


Acknowledgments


References




The following articles in journals at HighWire Press have cited this article:


Home page
 J Clin PharmacolHome page
O. Q. P. Yin, B. Tomlinson, A. H. L. Chow, M. M. Y. Waye, and M. S. S. Chow
Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability
J. Clin. Pharmacol., June 1, 2004; 44(6): 582 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Borlak and T. Thum
Identification of Major CYP2C9 and CYP2C19 Polymorphisms by Fluorescence Resonance Energy Transfer Analysis
Clin. Chem., September 1, 2002; 48(9): 1592 - 1594.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.